Drug Trial Radar · NCT01708603
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jan 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,831
Actual
Start
Aug 2012
Primary completion
Sep 2014
Study completion Oct 2015
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumabDrug
210 mg brodalumab administered SC
140 mg brodalumabDrug
140 mg brodalumab administered SC
ustekinumabDrug
45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
placeboDrug
Placebo administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12Time frame: 12 weeks
- Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12Time frame: 12 weeks
- Percentage of Participants With Psoriasis Area Severity Index (PASI) 100 at Week 12Time frame: 12 Weeks
Locations
153 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Tucson, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Bakersfield, California
Research Site
Beverly Hills, California
Research Site
Irvine, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Sacramento, California
Research Site
San Diego, California
Research Site
San Diego, California
Research Site
Vista, California
Research Site
Denver, Colorado
Research Site
Denver, Colorado
Research Site
Denver, Colorado
Research Site
New Haven, Connecticut
Research Site
Aventura, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Pembroke Pines, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Newnan, Georgia
Research Site
Snellville, Georgia
Research Site
Chicago, Illinois
Research Site
Chicago, Illinois
Research Site
Skokie, Illinois
Research Site
Carmel, Indiana
Research Site
Plainfield, Indiana
Research Site
South Bend, Indiana
Research Site
Louisville, Kentucky
Research Site
Lake Charles, Louisiana
Research Site
Lake Charles, Louisiana
Research Site
New Orleans, Louisiana
Research Site
Rockville, Maryland
Research Site
Silver Spring, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
North Andover, Massachusetts
Research Site
Ann Arbor, Michigan
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.